A nootropic peptide with a Cold-War backstory and a surprisingly deep research record.
Semax is one of those compounds that sounds obscure in the West but has decades of use behind it elsewhere. It came out of Soviet and later Russian neuroscience, and it’s still studied seriously today — which makes it far more than a novelty.
What it is
Semax is a short synthetic peptide based on a fragment of ACTH (adrenocorticotropic hormone) — specifically the ACTH(4–10) region — but modified so that it no longer carries ACTH’s hormonal effects. What’s left is a peptide studied purely for its effects on the brain.
What the research looks at
The recurring theme is neuroprotection and cognition. A lot of the published work centres on BDNF (brain-derived neurotrophic factor), a protein involved in the growth and survival of neurons — Semax appears to influence its expression. From there the research touches attention, memory, and recovery of brain tissue after stress or reduced blood flow.
In Russia, Semax has actually been used clinically for years — an unusually mature history for a compound that remains research-only across most of the world.
Where it sits
Semax is the “sharper, more stimulating” half of the nootropic-peptide pair, usually discussed alongside its calmer sibling Selank — the two came from the same research lineage.
Handling in the lab
Lyophilised powder, reconstituted with bacteriostatic water and kept cold. ≥99% HPLC purity, Janoshik verified — certificate on the product page.
In the catalogue
Semax
Stocked in our UK warehouse at ≥99% HPLC purity, Janoshik independently tested.
